Loop Capital analyst Chris Dankert keeps a Hold rating and $255 price target on Nordson (NDSN) but notes that the company’s $800M acquisition of Atrion (ATRI) is an “excellent addition” and the type of deal that the firm hopes to continue seeing. The deal will expand Nordson’s medical solutions portfolio into clear adjacencies including fluid management for oncology, cardiovascular, and infusion applications, even if its near-term earnings accretion is somewhat weighed down by financing costs, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NDSN:
- Nordson to acquire Atrion for $460 per share in cash
- Nordson to acquire Atrion for $460.00 per share in cash
- Nordson price target lowered to $295 from $315 at DA Davidson
- Nordson price target lowered to $272 from $303 at Baird
- Nordson cuts FY24 EPS view to $9.35-$9.75 from $10-$10.50, consensus $10.23
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue